Demonstrates enhanced tumor immunity in cancers using a novel microneedle platform for immunomodulation.
Solid tumors characterized by intrinsically low immunogenicity and a profoundly immunosuppressive microenvironment remain largely refractory to current cancer immunotherapies. Here, a photoactivatable nanozyme-integrated microneedle platform (HTHPH MNs) is developed to enable spatiotemporally controlled immunomodulation via a self-cascaded immunogenic cell death (ICD)-stimulator of interferon genes (STING) amplification circuit. Hollow mesoporous Prussian blue (HMPB) nanozymes coloaded with hydroxyurea (HU) and thapsigargin (TG) are embedded within a poly(γ-glutamic acid) microneedle matrix, allowing localized and minimally invasive intratumoral delivery. Upon near-infrared irradiation, the nanozymes simultaneously induce mild hyperthermia and catalyze endogenous hydrogen peroxide into highly reactive hydroxyl radicals, suppressing heat shock protein-mediated thermotolerance and triggering robust ICD. HU inhibits DNA replication and repair, promoting cytosolic double-stranded DNA accumulation and activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, while TG induces endoplasmic reticulum Ca²⁺ depletion to relieve stromal interaction molecule 1 (STIM1)-mediated inhibition of STING trafficking, thereby amplifying type I interferon signaling. This trimodal self-amplifying immune cascade enhances tumor immunogenicity, remodels the tumor immune microenvironment, and elicits potent local and systemic T cell-mediated antitumor responses. Collectively, this work establishes a nanozyme-microneedle-integrated strategy for the precise orchestration of innate and adaptive antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: